Why is Medro's three-month price above its month-to-month price?

Nothing on the site explains it. Semaglutide is published at $149 with no commitment and $179 on a three-month term; tirzepatide at $224 and $269. It reads either as a labeling error or as a tier structure that has not been described.

Does a longer term save money here?

Not against the month-to-month rate. Six months is published at $159 on semaglutide, $10 above the $149 no-commitment figure, and the twelve-month tier returns to $149 exactly. Tirzepatide has the same shape, landing on $224 at both ends.

Are these prices firm?

No. Medro labels them illustrative and says the final price is shown before checkout, and that it may vary by dose, pharmacy or eligibility. Every rung on the ladder carries that qualifier, so each is an indication rather than a rate.

Can a brand-name GLP-1 be prescribed here?

Brand-name GLP-1 options are offered alongside the compounded ones. Those are FDA-approved products, which the compounded versions are not, and their pricing sits outside the published compounded ladder.

Medro is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.

Is Medro expensive compared with other GLP-1 telehealth sellers providers?

Medro publishes a starting figure of $149/mo. Across the 115 GLP-1 telehealth sellers providers we review that publish a single monthly figure, those run $76 to $369 with a median of $170, which puts Medro below the median, toward the cheaper end. The other 5 GLP-1 telehealth sellers providers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.

Updated September 2026

Medro review

Illustrative, and oddly ordered

$149 a month to month for semaglutide, with the three-month tier published at $179 — above the figure a commitment is supposed to beat.

Our verdict

Medro's published ladder does not descend: semaglutide is $149 month to month, then $179 on three months, $159 on six and $149 on twelve. Tirzepatide runs $224, $269, $239 and $224 across the same rungs, so on both molecules the three-month tier sits above the no-commitment rate and the twelve-month rung returns to it. That is either a labeling error or a tier structure nobody has described, and the site does not settle which. Every figure is marked illustrative in any case, with the final price shown before checkout, so none of them is a quote.

Disclosure: GLP Loss is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Check availability →

At a glance

Category: GLP-1 telehealth
Molecule: Semaglutide · Tirzepatide
Form: Injection
States: 50
Prescription: Required
Compounded: Yes — not FDA-approved
Pharmacy: Not named
Availability: 50 states
Updated: September 2026

What it is

A fifty-state telehealth service offering compounded semaglutide and tirzepatide by injection alongside brand-name GLP-1 options, with every compounded figure published as an illustration rather than a fixed price.

How it works

Four term lengths are published on each compounded molecule: month to month, three months, six months and twelve. A disclaimer attaches to all of them — the final price is shown before checkout, and may vary by dose, pharmacy or eligibility. Brand-name GLP-1 options are offered beside the compounded ones.

Pricing transparency

Compounded semaglutide is published at $149 month to month, $179 on a three-month term, $159 on six months and $149 on twelve. Compounded tirzepatide is $224, $269, $239 and $224 across those same four rungs. On both, the three-month tier is quoted above the month-to-month figure, and the twelve-month tier matches it exactly. Medro describes the whole ladder as illustrative.

Branded vs compounded

Compounded semaglutide and tirzepatide by injection, plus brand-name GLP-1 products. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before dispensing. The brand-name options are FDA-approved medications dispensed as the manufacturer supplies them, and their pricing is not part of the published compounded ladder.

Pros and watch-outs

What we like

Four term lengths published on both molecules
The illustrative caveat is stated, not buried
Brand-name options offered beside compounded
Fifty states

Watch-outs

The three-month tier is above month to month
Twelve months costs the same as no commitment
No figure on the ladder is a firm quote
Dose, pharmacy and eligibility can all move it

Best for

Buyers weighing compounded against brand inside one intake.

Who should look elsewhere

Anyone who needs the published number to be the charged one.

How Medro compares

A few alternatives worth a look, depending on what you’re optimizing for.

SkinnyRx
A discounted rate, if it lasts
See SkinnyRx →
Bodybuilding Health+
A headline that is the month-to-month rate
See Bodybuilding Health+ →
Oak
Flat dose pricing without a subscription
See Oak →

Compare all providers side by side →

More GLP-1 telehealth sellers reviews: LifeMDLongevixxLttlLuvo HealthMadeMedMaximus

Hana Brennan

Pricing & provider data · Reviewed and last verified September 2026

How we assessed this. This review reflects GLP Loss’s own read of Medro’s publicly-stated model — pricing transparency, clinical oversight, medication clarity, and access — against our editorial methodology. We publish no fabricated ratings or first-hand outcomes. A partnership never changes the assessment — see how we make money.

Frequently asked

Why is Medro's three-month price above its month-to-month price?: Nothing on the site explains it. Semaglutide is published at $149 with no commitment and $179 on a three-month term; tirzepatide at $224 and $269. It reads either as a labeling error or as a tier structure that has not been described.
Does a longer term save money here?: Not against the month-to-month rate. Six months is published at $159 on semaglutide, $10 above the $149 no-commitment figure, and the twelve-month tier returns to $149 exactly. Tirzepatide has the same shape, landing on $224 at both ends.
Are these prices firm?: No. Medro labels them illustrative and says the final price is shown before checkout, and that it may vary by dose, pharmacy or eligibility. Every rung on the ladder carries that qualifier, so each is an indication rather than a rate.
Can a brand-name GLP-1 be prescribed here?: Brand-name GLP-1 options are offered alongside the compounded ones. Those are FDA-approved products, which the compounded versions are not, and their pricing sits outside the published compounded ladder.
Is Medro legit?: Medro is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
Is Medro expensive compared with other GLP-1 telehealth sellers providers?: Medro publishes a starting figure of $149/mo. Across the 115 GLP-1 telehealth sellers providers we review that publish a single monthly figure, those run $76 to $369 with a median of $170, which puts Medro below the median, toward the cheaper end. The other 5 GLP-1 telehealth sellers providers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.

Check availability →

Or compare every seller we cover.